Showing 1 - 5 results of 5 for search 'Mitzi J. Williams', query time: 0.02s Refine Results
  1. 1
    A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis

    A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis by Laura Airas, Robert A. Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J. Williams, Bernd C. Kieseier, Heinz Wiendl

    Published 2024-04-01
    Get full text
    Article
  2. 2
    Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

    Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM by Angel Chinea, Lilyana Amezcua, Wendy Vargas, Annette Okai, Mitzi J. Williams, Ray Su, Becky Parks, Jason P. Mendoza, James B. Lewin, Cynthia C. Jones

    Published 2020-05-01
    Get full text
    Article
  3. 3
    Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM

    Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM by Mitzi J. Williams, Lilyana Amezcua, Annette Okai, Darin T. Okuda, Stanley Cohan, Ray Su, Becky Parks, Jason P. Mendoza, James B. Lewin, Cynthia C. Jones

    Published 2020-05-01
    Get full text
    Article
  4. 4
    Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM

    Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM by Mitzi J. Williams, Lilyana Amezcua, Angel Chinea, Stanley Cohan, Annette Okai, Darin T. Okuda, Wendy Vargas, Nick Belviso, Ivan Božin, Xiaotong Jiang, James B. Lewin, Jennifer Lyons, Changyu Shen, Sarah M. England, Nydjie Grimes

    Published 2023-06-01
    Get full text
    Article
  5. 5
    Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

    Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study) by Annette F. Okai, Lilyana Amezcua, Regina R. Berkovich, Angel R. Chinea, Keith R. Edwards, Brian Steingo, Aljoeson Walker, Alan K. Jacobs, Nadia Daizadeh, Mitzi J. Williams, the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators

    Published 2019-10-01
    Get full text
    Article

Search Tools: